Detail akcie Legend Biotc Sp ADS online

Business Summary: Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Legend Biotech Corp (ADR) revenues increased 64% to $722.4M. Net loss increased 31% to $266M. Revenues reflect Collaboration revenue increase from $314.6M to $667.2M. Higher net loss reflects Other decrease of 94% to $3M (income), Selling and distribution expenses increase of 44% to $141.6M (expense), Research and development expenses increase of 1% to $313.4M (expense).